HRAS and neoplasm: Briefly, the first step of this protocol consists of applying the mutagenic substance 7,12-dimethylbenz[a]anthracene (DMBA) to induce an activating mutation in the HRAS oncogene, whereas the second step uses a promoting agent such as 12-O-tetradecanoylphorbol-13-acetate (TPA) to create an inflammation-rich and tumor-prone microenvironment22.